Reneo Pharmaceuticals EBIT

Reneo Pharmaceuticals (RPHM) currently reports a EBIT of $-62M as of June 2026. That compares with $-2M in the prior-year period — down 3040.4% year over year. That is below the Healthcare sector average of $22B. Use the charts on this page to explore Reneo Pharmaceuticals's EBIT history and peer comparisons.

Reneo Pharmaceuticals's EBIT decreased from $-2M to $-62M — a 3040.4% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Reneo Pharmaceuticals's EBIT of $-62M is lower than the Healthcare sector average of $22B. That is roughly 100.3% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Reneo Pharmaceuticals reported $-62M in EBIT as of June 2026. That compares with $-2M in the prior-year period — down 3040.4% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $-62M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $22B. From there, open related valuation or income-statement pages for Reneo Pharmaceuticals, and consider following RPHM for alerts when major investors trade the stock.